ALK-B.CO - ALK-Abelló A/S
ALK-Abelló A/S
Boge Alle 6-8
Horsholm 2970
Denmark
45 45 74 75 76
https://www.alk.net
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,712
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Carsten Hellmann | Pres, CEO & Member of Management Board | 14.37M | N/A | 1964 |
| Mr. Søren Daniel Niegel | Exec. VP of Commercial Operations & Member of Management Board | 5.8M | N/A | 1971 |
| Ms. Katja Barnkob Thalund | Project Director of Global CMC Devel. & Employee-elected Director | 350k | N/A | 1969 |
| Mr. Claus Steensen Solje | Exec. VP, CFO & Member of Management Board | N/A | N/A | 1962 |
| Dr. Henriette Mersebach | Exec. VP R&D & Member of Management Board | N/A | N/A | N/A |
| Mr. Per Plotnikof | VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR | N/A | N/A | N/A |
| Prof. Hendrik Kees Kam Nolte M.D., Ph.D. | Sr. VP of Research & Devel. - North America and International Markets | N/A | N/A | N/A |
| Mr. Christian G. Houghton | Head of Product Supply | N/A | N/A | N/A |
Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Corporate governance
ALK-Abelló A/S’s ISS governance QualityScore as of 1 June 2023 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 10; Compensation: 2.
